文献速递炎症性肠病

早期药物及抗英夫利西单抗抗体水平对英夫利西单抗治疗原发性无应答的预测

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
PubMed 文献 · Aliment Pharmacol Ther · 2017-11-09

这项回顾性观察性病例对照研究在炎症性肠病患者中评估第2周和第6周诱导期英夫利西单抗及抗英夫利西单抗抗体水平与原发性无应答的关系。原发无应答者第2周和第6周英夫利西单抗水平均显著低于应答者,抗英夫利西单抗抗体出现更频繁且水平更高。第2周英夫利西单抗水平低于6.8 μg/mL和抗英夫利西单抗抗体水平高于4.3 μg/mL-eq与原发性无应答相关,尤其在克罗恩病患者中。

要点

  • 第2周和第6周英夫利西单抗水平在原发无应答者中显著低于应答者。
  • 原发无应答者抗英夫利西单抗抗体出现更频繁且水平更高。
  • 第2周英夫利西单抗水平低于6.8 μg/mL和抗英夫利西单抗抗体高于4.3 μg/mL-eq与原发性无应答相关。

核心结论

  • 第2次输注前英夫利西单抗水平低于6.8 μg/mL和抗英夫利西单抗抗体水平高于4.3 μg/mL-eq与原发性无应答相关,尤其在克罗恩病患者中。

研究设计与样本

  • 回顾性观察性病例对照研究,纳入2009年至2016年在Sheba医疗中心接受英夫利西单抗治疗并随访的炎症性肠病患者。
  • 识别35例原发无应答者,按1:3比例匹配105例原发应答者。
  • 采用耐受药物的ELISA法测定输注前英夫利西单抗和抗英夫利西单抗抗体水平。

主要发现

  • 第2周和第6周英夫利西单抗水平在原发无应答者中显著低于应答者(第2周中位数7.2 μg/mL vs 13.5 μg/mL,P=0.0019;第6周中位数2.2 μg/mL vs 9.5 μg/mL,P<0.0001)。
  • 抗英夫利西单抗抗体在第2周或第6周出现更频繁(68% vs 28%,P=0.0004),且水平更高(第2周中位数7.3 μg/mL-eq vs 3.8 μg/mL-eq,P=0.005;第6周中位数10.8 μg/mL-eq vs 4.4 μg/mL-eq,P=0.008)。
  • 第2周英夫利西单抗水平低于6.8 μg/mL可预测原发性无应答(AUC=0.68,P=0.002,敏感性50%,特异性86%)。
  • 第2周抗英夫利西单抗抗体水平高于4.3 μg/mL-eq可预测原发性无应答(AUC=0.78,P=0.0004,敏感性77%,特异性71%)。
  • 较高的基线溃疡性结肠炎临床评分、英夫利西单抗单药治疗、既往阿达木单抗治疗和既往克罗恩病相关手术也与原发性无应答风险增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined. AIM: To evaluate the association of early (week 2 and week 6) induction infliximab and anti-infliximab antibody levels with primary nonresponse. METHODS: A retrospective observational case-control study of inflammatory bowel disease patients treated with infliximab and followed at Sheba Medical Center between 2009 and 2016 was performed. Pre-infusion infliximab and antibodies to infliximab (ATI) levels were measured by our previously described drug-tolerant ELISA assay. RESULTS: Thirty-five primary nonresponders have been identified and matched with 105 primary responders (1:3 ratios). Both week 2 and week 6 infliximab levels were significantly lower among primary nonresponders compared to responders (week 2, 6: median level 7.2, 2.2 μg/mL vs 13.5, 9.5 μg/mL, P = .0019, P < .0001 respectively). Antibodies to infliximab appeared more frequently (either week 2 or 6, 68% vs 28% prevalence, P = .0004) and at higher levels in nonresponders compared to responders (week 2, 6: median ATI 7.3, 10.8 μg/mL-eq vs 3.8, 4.4 μg/mL-eq, P = .005, P = .008 respectively). Moreover, week 2 infliximab levels <6.8 μg/mL (AUC = 0.68, P = .002, sensitivity 50%, specificity 86%) and antibodies to infliximab levels >4.3 μg/mL-eq (AUC = 0.78, P = .0004, sensitivity 77%, specificity 71%) were predictive of primary nonresponse. Among the other clinical and demographic variables, higher baseline ulcerative colitis clinical score, infliximab monotherapy, prior adalimumab therapy and previous Crohn's disease-related surgeries were also associated with an increased risk of primary nonresponse. CONCLUSIONS: Infliximab levels below 6.8 μg/mL and antibodies to infliximab levels above 4.3 μg/mL-eq before the second infusion are associated with primary nonresponse, especially among Crohn's disease patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther. 2017. PMID: 29124774. doi:10.1111/apt.14410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。